Lung Cancer
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. 
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
The approval is for the first-line treatment of advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions.
The ORR of the external control group was 3%, while it was 36.8% in those who received amivantamab for NSCLC.
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
The FDA action date for its regulatory decision is anticipated during the third quarter of this year.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Advertisement
Expert Interviews on Oncology
Advertisement
DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.